CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Medtronic has reported revenue gains across several of its medical device franchises, leading the company to ... aortic valve ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

The device demonstrated superior bleeding risk Reduction to oral Anticoagulation following a Cardiac Ablation in the trial. The data also demonstrated that the stroke risk reduction device is as ...

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...